Studies on Gymnemic Acids Nanoparticulate Formulations against Diabetes Mellitus

The solid dosage forms of Gymnemic acid nanoparticulate formulations developed earlier were tested for anti-diabetic activity and hypoglycemic activity. Glucose, insulin and various biochemical parameters were monitored from blood samples of rats to study the efficacy of these formulations. The nanoformulations exhibited significant anti-hyperglycemic activity and produced substantial hypoglycemia. Blood glucose levels (mg/dL) in glucose loaded hyperglycemic rats after dosing with Gymnemic acids nano-formulations were 79 to 98, as against 105 in the control after 3 hours. Hypoglycemic activity of Gymnemic acids nano-formulations ranged between 63 to 66 (Blood glucose concentration, mg/dL) as against 80 in the control. Biochemical parameters studied also supported the above observations. The study clearly shows that gymnemic acid nanoparticulate formulations developed may be a better therapeutic adjunctive option for diabetes mellitus in humans.